The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
A review of Dengvaxia®: development to deployment
Open accessAbstract
Dengue is the world's most prevalent and important arboviral disease. More than 50% of the world's population lives at daily risk of infection and it is estimated more than 95 million people a year seek medical care following infection. Severe disease can manifest as plasma leakage and potential for clinically significant hemorrhage, shock, and death. Treatment is supportive and there is currently no licensed anti-dengue virus prophylactic or therapeutic compound. A single dengue vaccine, Sanofi Pasteur's Dengvaxia®, has been licensed in 20 countries but uptake has been poor. A safety signal in dengue seronegative vaccine recipients stimulated an international re-look at the vaccine performance profile, new World Health Organization recommendations for use, and controversy in the Philippines involving the government, regulatory agencies, Sanofi Pasteur, clinicians responsible for testing and administering the vaccine, and the parents of vaccinated children. In this review, we provide an overview of Dengvaxia's® development and discuss what has been learned about product performance since its licensure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The global distribution and burden of dengue
Bhatt, S., Gething, P. W., Brady, O. J., Messina, J. P., Farlow, A. W., Moyes, C. L., Drake, J. M., Brownstein, J. S., Hoen, A. G., Sankoh, O., et al. (2013) · Nature · doi:10.1038/nature12060 · Cited by 10,037 · cited 1×
“It is estimated there are over 390 million infections globally each year of which more than 95 million are clinically apparent.(3) There is no specific anti-DENV therapeutic, but supportive care is very effective when delivered by experienced practitioners.”
Dengue Viremia Titer, Antibody Response Pattern, and Virus Serotype Correlate with Disease Severity
Vaughn, D. W., Green, S., Kalayanarooj, S., Innis, B. L., Nimmannitya, S., Suntayakorn, S., Endy, T. P., Raengsakulrach, B., Rothman, A. L., Ennis, F. A., et al. (2000) · The Journal of Infectious Diseases · doi:10.1086/315215 · Cited by 1,632
Kuhn, R. J., Zhang, W., Rossmann, M. G., Pletnev, S. V., Corver, J., Lenches, E., Jones, C. T., Mukhopadhyay, S., Chipman, P. R., Strauss, E. G., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00660-8 · Cited by 1,563
Guzman, M. G., & Harris, E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)60572-9 · Cited by 1,345
Halstead, S. B. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61687-0 · Cited by 1,287
Dengue, Urbanization and Globalization: The Unholy Trinity of the 21st Century
Gubler, D. J. (2011) · Tropical Medicine and Health · doi:10.2149/tmh.2011-s05 · Cited by 1,098
Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease
Hadinegoro, S. R., Arredondo-García, J. L., Capeding, M. R., Deseda, C., Chotpitayasunondh, T., Dietze, R., Hj Muhammad Ismail, H. I., Reynales, H., Limkittikul, K., Rivera-Medina, D. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506223 · Cited by 1,077
Capeding, M. R., Tran, N. H., Hadinegoro, S. R. S., Ismail, H. I. H. M., Chotpitayasunondh, T., Chua, M. N., Luong, C. Q., Rusmil, K., Wirawan, D. N., Nallusamy, R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61060-6 · Cited by 973
Self-citationEfficacy of a Tetravalent Dengue Vaccine in Children in Latin America
Villar, L., Dayan, G. H., Arredondo-García, J. L., Rivera, D. M., Cunha, R., Deseda, C., Reynales, H., Costa, M. S., Morales-Ramírez, J. O., Carrasquilla, G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411037 · Cited by 942
Sabchareon, A., Wallace, D., Sirivichayakul, C., Limkittikul, K., Chanthavanich, P., Suvannadabba, S., Jiwariyavej, V., Dulyachai, W., Pengsaa, K., Wartel, T. A., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61428-7 · Cited by 818
Cited by
A perspective on potential antibody-dependent enhancement of SARS-CoV-2
Arvin, A. M., Fink, K., Schmid, M. A., Cathcart, A., Spreafico, R., Havenar-Daughton, C., Lanzavecchia, A., Corti, D., & Virgin, H. W. (2020) · Nature · doi:10.1038/s41586-020-2538-8 · Cited by 485
Prospects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Metadata
- Authors
- Thomas, S. J., & Yoon, I.-K.
- Venue
- Human Vaccines & Immunotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2019-10-03
- Volume
- 15
- Issue
- 10
- Pages
- 2295-2314
- ISSN
- 2164-5515 (ISSN-L)
- 2164-554X
- OpenAlex
- W2978577943
- Cited by
- 331
- References
- 69
- FWCI
- 31.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A review of Dengvaxia®: development to deployment. https://app.cochat.ai/papers/10.1080/21645515.2019.1658503
- The paper
- Thomas, S. J., & Yoon, I.-K. (2019). A review of Dengvaxia®: development to deployment. Human Vaccines & Immunotherapeutics. https://doi.org/10.1080/21645515.2019.1658503
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
